OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

By S. Aurora, Dw Dodick, C. Turkel, R. DeGryse, S. Silberstein, R. Lipton, H. Diener, MF Brin. Cephalalgia, 2010

899 citations recorded by the source corpus.

Subfields: Epidemiology, Neurology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/5fac65f17f4a299dd0618b49c20da5d3cd04e688

Citations in the corpus

• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program (2010, neutral): “—Inclusion and exclusion criteria of the individual PREEMPT studies were the same and are described elsewhere.(32,33) Briefly, eligible patients were men or women aged 18-65 years with a history of migraine meeting the diagnostic criteria listed in ICHD-II (2004) Section 1, Migraine,(4) with “compli”